{"id":"NCT02795117","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05","primaryCompletion":"2017-02","completion":"2017-02","firstPosted":"2016-06-09","resultsPosted":"2021-01-05","lastUpdate":"2021-11-02"},"enrollment":486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"Ivermectin","otherNames":[]},{"type":"DRUG","name":"Ivermectin (reference)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea","primaryOutcome":{"measure":"Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count","timeFrame":"Day 1 to Day 84","effectByArm":[{"arm":"Test Product","deltaMin":65.47,"sd":30.222},{"arm":"Reference Product","deltaMin":67.89,"sd":30.244},{"arm":"Placebo","deltaMin":55.51,"sd":32.66}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":193},"commonTop":[]}}